MAINTENANCE VS INTERMITTENT INHALED STEROIDS IN WHEEZING TODDLERS (MIST)

喘息幼儿的维持与间歇性吸入类固醇(雾)

基本信息

  • 批准号:
    8166632
  • 负责人:
  • 金额:
    $ 2.03万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-12-01 至 2010-06-30
  • 项目状态:
    已结题

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Preschool children with frequent recurrent and intermittent wheezing episodes requiring systemic corticosteroids or ER visits/hospitalizations are a major public health challenge. This group of younger asthmatic children has two major deleterious characteristics compared to older asthmatic children: (1) they suffer greater risk of increased health care utilization and mortality and (2) they experience less favorable responses to asthma management strategies. The National Asthma Education and Prevention Program (NAEPP) and Global Initiative for Asthma require more clinical evidence to define optimal treatment options for these children to reduce acute episodes and impairment related to symptom burden. NAEPP guidelines emphasize two major domains of asthma control: risk and impairment. Risk addresses exacerbation frequency/severity, loss of lung function, and medication side effects. Impairment/burden refers to symptoms, school/work absences, exercise problems, nocturnal awakenings, and current pulmonary function. This study involves 250 well-characterized high-risk API positive children age 12-53 months, with a history of a severe exacerbation in the prior year. Study questions are: 1. Is maintenance low-dose ICS more effective than intermittent high-dose ICS administered during RTI on modifying the risk (rate of an exacerbation requiring systemic corticosteroids is the primary outcome) and impairment domains of recurrent asthma? 2. Are there demographic or asthma/atopic features or CD14-159 genotypes and other genotypes related to ICS responsiveness? 3. Are there are differences in treatment associated adverse effects with these two ICS regimens? 4. Which viruses are associated with exacerbations and which, if any, ICS regimen is better able to ameliorate these exacerbations?
这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者(PI)可能从另一个NIH来源获得了主要资金, 因此可以在其他CRISP条目中表示。所列机构为 研究中心,而研究中心不一定是研究者所在的机构。 学龄前儿童经常反复发作和间歇性喘息发作,需要全身性皮质类固醇或急诊室就诊/住院治疗,这是一个重大的公共卫生挑战。 与年龄较大的哮喘儿童相比,这组年龄较小的哮喘儿童具有两个主要的有害特征:(1)他们遭受更大的医疗保健利用和死亡率增加的风险,(2)他们对哮喘管理策略的反应不太有利。国家哮喘教育和预防计划(NAEPP)和全球哮喘倡议需要更多的临床证据来确定这些儿童的最佳治疗方案,以减少与症状负担相关的急性发作和损害。NAEPP指南强调哮喘控制的两个主要领域:风险和损害。 风险涉及急性加重频率/严重程度、肺功能丧失和药物副作用。损伤/负担是指症状、缺课/工作、运动问题、夜间觉醒和当前肺功能。 本研究涉及250例特征明确的高危API阳性儿童,年龄12-53个月,前一年有严重急性发作史。研究问题包括: 1.在RTI期间维持低剂量ICS是否比间歇性高剂量ICS更有效地改变复发性哮喘的风险(需要全身皮质类固醇的急性发作率是主要结局)和损害领域? 2.是否存在与ICS反应性相关的人口统计学或哮喘/特应性特征或CD 14 -159基因型和其他基因型? 3.这两种ICS方案的治疗相关不良反应是否存在差异? 4.哪些病毒与急性加重相关,如果有,哪种ICS方案能够更好地改善这些急性加重?

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

HENGAMEH RAISSY其他文献

HENGAMEH RAISSY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('HENGAMEH RAISSY', 18)}}的其他基金

TREATING CHILDREN TO PREVENT EXACERBATIONS OF ASTHMA (TREXA)
治疗儿童预防哮喘恶化 (TREXA)
  • 批准号:
    8166624
  • 财政年份:
    2009
  • 资助金额:
    $ 2.03万
  • 项目类别:
EVALUATION OF THE BRONCHOPROTECTIVE EFFECT OF ARFORMOTEROL IN CHILDREN WITH
阿福特罗对患有以下疾病的儿童的支气管保护作用的评估
  • 批准号:
    8166621
  • 财政年份:
    2009
  • 资助金额:
    $ 2.03万
  • 项目类别:
MATERNAL AND INFANT IMMUNITY TO PERTUSSIS
母亲和婴儿对百日咳的免疫力
  • 批准号:
    7952050
  • 财政年份:
    2008
  • 资助金额:
    $ 2.03万
  • 项目类别:
EVALUATION OF THE BRONCHOPROTECTIVE EFFECT OF ARFORMOTEROL IN CHILDREN WITH
阿福特罗对患有以下疾病的儿童的支气管保护作用的评估
  • 批准号:
    7952082
  • 财政年份:
    2008
  • 资助金额:
    $ 2.03万
  • 项目类别:
PRETREATMENT WITH ALBUTEROL VS MONTELUKAST IN EXERCISE INDUCED BRONCHOSPASM IN
沙丁胺醇与孟鲁司特预处理在运动诱发的支气管痉挛中的比较
  • 批准号:
    7716587
  • 财政年份:
    2008
  • 资助金额:
    $ 2.03万
  • 项目类别:
TREATING CHILDREN TO PREVENT EXACERBATIONS OF ASTHMA (TREXA)
治疗儿童预防哮喘恶化 (TREXA)
  • 批准号:
    7952085
  • 财政年份:
    2008
  • 资助金额:
    $ 2.03万
  • 项目类别:
MATERNAL AND INFANT IMMUNITY TO PERTUSSIS
母亲和婴儿对百日咳的免疫力
  • 批准号:
    7716593
  • 财政年份:
    2008
  • 资助金额:
    $ 2.03万
  • 项目类别:
PRETREATMENT WITH ALBUTEROL VS MONTELUKAST IN EXERCISE INDUCED BRONCHOSPASM IN
沙丁胺醇与孟鲁司特预处理在运动诱发的支气管痉挛中的比较
  • 批准号:
    7606898
  • 财政年份:
    2006
  • 资助金额:
    $ 2.03万
  • 项目类别:
MATERNAL AND INFANT IMMUNITY TO PERTUSSIS
母亲和婴儿对百日咳的免疫力
  • 批准号:
    7606904
  • 财政年份:
    2006
  • 资助金额:
    $ 2.03万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 2.03万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 2.03万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 2.03万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 2.03万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 2.03万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 2.03万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 2.03万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 2.03万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 2.03万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 2.03万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了